title: [Treatment of recurrent ovarian cancer--a retrospective study].
abstract: BACKGROUND
  Treatment of recurrent ovarian cancer is not standardized. Pre-clinical tests have confirmed the synergistic effect of gemcitabine and platinum, which can break through drug resistance to platinum. Therefore, efficacy of a combined gemcitabine and platinum-based regimen can be expected not only in therapy platinum-sensitive but also in platinum-resistant disease. Surgery--so-called secondary (eventually tertiary) cytoreductive surgery, should be considered in recurrent disease before planning the chemotherapy.
  
  
  METHODS
  This is a retrospective analysis of 58 patients with recurrent ovarian cancer treated with a gemcitabine and platinum-based regimen (GP) as the second or third-line chemotherapy. Some of the patients underwent secondary cytoreductive surgery before starting the systemic treatment. The aim of the study was to detect the response rate, progression-free survival and overall survival in the whole group of patients and in subgroups with platinum-sensitive and platinum-resistant disease. Another aim was to detect the correlation between secondary cytoreductive surgery and the efficacy of chemotherapy.
  
  
  RESULTS
  Systemic treatment (GP) has helped to achieve a response rate of 53.5%, with time to progression 10 months and overall survival 23.5 months. A better response rate, progression free survival and overall survival were achieved in the group of patients with platinum-sensitive disease compared to patients with platinum-resistant disease, but this difference was not statistically significant. 20 patients underwent effective secondary cytoreductive surgery before the systemic treatment. Patients who underwent effective secondary cytoreductive surgery had a statistically better response rate (RR: 80% vs 39.5%), longer progression-free survival (PFS: 13.5 m vs 9 m, p = 0.006) and longer overall survival (OS: 40 m vs 16.9 m, p = 0.006) when compared to patients without secondary cytoreductive surgery.
  
  
  CONCLUSIONS
  We have confirmed the efficacy of a gemcitabine and platinum-based regimen in the therapy of recurrent ovarian cancer, in both platinum-sensitive and platinum-resistant disease. An important prognostic factor in the whole group of patients was the realization of effective secondary cytoreductive surgery.
authors.affiliation: I. Onkologická klinika LF UK a OUSA, Heydukova 10, 812 50 Bratislava, Slovenská republika. lickovamarcela@yahoo.com
authors.forename: M
authors.initials: M
authors.lastname: Tkácová
authors.forename: B
authors.initials: B
authors.lastname: Belohorská
authors.forename: K
authors.initials: K
authors.lastname: Sevcíková
authors.forename: L
authors.initials: L
authors.lastname: Hel'pianska
authors.forename: D
authors.initials: D
authors.lastname: Ondrus
authors.forename: M
authors.initials: M
authors.lastname: Ondrusová
authors.forename: S
authors.initials: S
authors.lastname: Spánik
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000601:surgery / Q000628:therapy*